Company Profile
Year Established :
1996
Total Assets(USD) :
choose not to disclose
Total Number of Staff :
90 to 99
Main Competitive Advantages :
Brandname,Experienced R&D Staff
Business Type :
Manufacturer
R&D Capacity :
Own brand
Annual Turnover(USD) :
choose not to disclose
Main Sales Markets :
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Main Product Categorise :
Active Pharmaceutical Ingredients
Jiangsu Weiqida Pharmaceutical Co., Ltd. (formerly known as Shanghai Shyndec Pharmaceutical (Haimen) Co., Ltd.) is a subsidiary of Shanghai Shyndec Pharmaceutical Co., Ltd., which is the chemical pharmaceutical industrial platform of China National Medicines Corporation Ltd (Sinopharm Group) and listed on the Shanghai Stock Exchange (stock code: 600420). Founded in February 2010 and headquartered in Nantong, Jiangsu Province, with a registered capital of RMB 800 million, the company is positioned as a high-end and distinctive R&D and manufacturing base for active pharmaceutical ingredients, with products mainly covering the fields of anti-infective, endocrine, cardiovascular and cerebrovascular disease, anticancer, antidepressant, and health products, which are exported to more than 20 countries and regions worldwide. The company is dedicated to becoming a professional, service-oriented, innovative, and reliable pharmaceutical service platform. After years of accumulation, we have a complete production technology capability and a comprehensive quality management and EHS management system, providing core services from pilot-scale fermentation to commercial-scale production and various certification and registration application supports for global customers. The company has successively passed authority certifications such as NMPA, FDA, and WHO, providing long-term services to world-renowned pharmaceutical companies.
The company has an R&D/technical center, relying on China State Institute of Pharmaceutical Industry Co.,Ltd, another subsidiary of Sinopharm Group, with powerful R&D technology, professional talent team, and advanced equipment and instruments. It has obtained the National Intellectual Property Management Certification and is recognized as a "Jiangsu High-Tech Enterprise", "Jiangsu High-end API Synthesis Engineering Technology Research Center", "Jiangsu Enterprise Technology Center", and "Jiangsu Integrity Pharmaceutical Enterprise". Azithromycin, L-α-glycerylphosphorylcholine, and Nebivolol hydrochloride products have obtained high-tech product certification. With our technical team and quality system, we have the capability and experience to carry out high-tech, high-value-added, and low-emission CMO&CMDO services.